Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQWG4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $104,846
Award facts
- Contract value 100% obligated
- $104,846.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $104,846.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL autoinjector units. This firm fixed-price delivery order, issued on December 15, 2025, with an ultimate completion date of January 7, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award was funded by DLA and represents a discrete fulfillment under the broader pharmaceutical supply chain supporting Department of Defense healthcare operations.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.999 billion ceiling and extends through December 31, 2036. The PPV-G GEN V program, a cornerstone of DLA's $30.3 billion pharmaceutical acquisition strategy, establishes multiple regional prime vendor contractors to supply branded and generic prescription drugs, biologics, and medical consumables to military healthcare facilities worldwide. DMS Pharmaceutical Group's established track record across numerous delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system, with no identified subcontractors on this award.
Quick answers
Who was awarded contract SPE2DR26FQWG4?
SPE2DR26FQWG4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 15, 2025.
How much is contract SPE2DR26FQWG4 worth?
The government has obligated $104,846 on SPE2DR26FQWG4.
Is contract SPE2DR26FQWG4 an order under another contract?
Yes. SPE2DR26FQWG4 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWG4 competed?
The extent of competition for SPE2DR26FQWG4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award